PRODUCTS

Anesthesia

Etoricoxib

EXIB-90, EXIB-120

DISCLAIMER: The following contents are intended for healthcare professionals only. If you are a patient or general mass viewing this site, we advise you to clarify with your doctor any information you read herein.

Overview

EXIB (Etoricoxib) is a selective cyclooxygenase 2 (COX 2) inhibitor indicated for adults for the symptomatic relief of:

•    Osteoarthritis (OA)
•    Rheumatoid Arthritis (RA)
•    Ankylosing Spondylitis
•    Pain and signs of inflammation associated with Acute Gouty Arthritis
•    Moderate pain associated with dental surgery

The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient’s overall risks.

EXIB is bioequivalent to the innovator and is up to 42% more cost-effective than the leading innovator brand.

 

Description

Generic Name:

Etoricoxib

Brand Name:

Exib-90, Exib-120

Sizes:

n/a

Preparation:

90 mg and 120 mg film-coated tablets

Name of Manufacturer

Hiral Labs Limited

Place of Manufacturer:

India

Shelf Life

36 months

Storage Condition:

Store at temperatures not exceeding 30ºC

Packaging:

Alu/Alu Blister Pack x 10’s (Box of 30s)

FDA Registration:

DRP-10323-02 (Exib-90) / DRP-10322-04 (Exib-120)

Bupivacaine in Dextrose

BUPIVAXINE

DISCLAIMER: The following contents are intended for healthcare professionals only. If you are a patient or general mass viewing this site, we advise you to clarify with your doctor any information you read herein.

Overview

BUPIVAXINE is a local anesthetic agent of the amide type. Bupivacaine in Dextrose produces a moderate muscular relaxation of the lower extremities lasting 2-2.5 hours. The motor blockade of the abdominal muscles makes the solution suitable for performing abdominal surgery lasting 45-60 minutes. It is indicated as intrathecal spinal anesthesia in adults and children of all ages.

BUPIVAXINE was launched in December 2021 and is 41% more affordable than the leading brand.
BUPIVAXINE is manufactured by Jayson Pharmaceuticals, an ISO (9001:2015) certified and one of the leading pharmaceutical companies in Bangladesh.

 

Description

Generic Name:

Bupivacaine in Dextrose

Brand Name:

Bupivaxine

Sizes:

5 mg/80 mg

Preparation:

5 mg/80 mg per ml ampoule; DOSAGE FORM: Solution for Injection (Spinal)

Name of Manufacturer

Jayson Pharmaceuticals, Ltd.

Place of Manufacturer:

Bangladesh

Shelf Life

24 months

Storage Condition:

Store at temperature not exceeding 30 ͦC

Packaging:

In Alu/PVC tray containing 2 glass ampoules x 4 mL (Box of 10s)

FDA Registration:

DRP-8106-03

PARACETAMOL

IFIMOL

DISCLAIMER: The following contents are intended for healthcare professionals only. If you are a patient or general mass viewing this site, we advise you to clarify with your doctor any information you read herein.

Overview

IFIMOL is a premier brand in Paracetamol I.V. promoted in the country. It was included in the Top 200 hospital ethical Products based on Dec 2018 IQVIA Report. IFIMOL is a PREMIXED, READY-TO-USE solution containing a therapeutic dose of 1 g paracetamol for adults. It can be administered as an infusion with no side effects. Moreover, IFIMOL is considered as safest treatment for fever and pain management.

It is manufactured by one of the fastest-growing pharmaceutical companies in India —Unique Pharmaceutical Laboratories.

Delex Pharma has started marketing the product in May 2013. Due to the demand, DPII has made it available in almost major tertiary hospitals, likewise sold in Mercury Drug branches.

Description

Generic Name:

PARACETAMOL

Brand Name:

IFIMOL

Sizes:

10 mG / mL

Preparation:

10 mg/mL in 100 mL vial; Solution for Intravenous Infusion

Name of Manufacturer

Unique Pharmaceutical Laboratories

Place of Manufacturer:

India

Shelf Life

24 months

Storage Condition:

Store at temperature not exceeding 30 ͦC

Packaging:

USP Type I Flint glass vial (Box of 1’s)

FDA Registration:

DRP-392

IBUPROFEN

INTRAFEN

DISCLAIMER: The following contents are intended for healthcare professionals only. If you are a patient or general mass viewing this site, we advise you to clarify with your doctor any information you read herein.

Overview

INTRAFEN is the first and only Ibuprofen brand in I.V. preparation launched in the Philippines in August 2018. DPII is proud in initiating the availability of INTRAFEN, as it is recognized for its significance in treating severely ill patients. Study shows that Ibuprofen has been rated as the safest conventional Nonsteroidal anti-inflammatory drug (NSAID).

Delex Pharma acquires the product from Mefar, which is a leading pharmaceutical institution in Turkey. Moreover, it is among the reputable contract manufacturer of parenteral solutions for human and veterinary usage in ampoules, vials, BFS (blow-fill-seal), PFS (pre-filled syringes), and freeze-dried products.

INTRAFEN is available in selected Mercury Drug branches.

Description

Generic Name:

IBUPROFEN

Brand Name:

INTRAFEN

Sizes:

100 mG/mL (400 mg/ 4mL), (800 mG / 8mL)

Preparation:

100 mg/mL in 4 mL & 8 mL vials; Solution for Intravenous Infusion

Name of Manufacturer

Mefar Ilac Sanayii A.S.

Place of Manufacturer:

Turkey

Shelf Life

24 months

Storage Condition:

Store at temperature not exceeding 30 ͦC

Packaging:

4 mL in 6 mL-capacity USP Type I clear and colorless glass vial; 8 mL in 10 mL-capacity USP Type I clear and colorless glass vial

FDA Registration:

DR-XY46120 (4 mL); DR-XY46190 (8 mL)

KETOROLAC

KETOROLEX

DISCLAIMER: The following contents are intended for healthcare professionals only. If you are a patient or general mass viewing this site, we advise you to clarify with your doctor any information you read herein.

Overview

KETOROLEX is among the quality products of Delex Pharma. It is used primarily as a short-term treatment of moderate to severe pain in adults. This medication is a nonsteroidal anti-inflammatory drug (NSAID). 

KETOROLEX is manufactured by Myungmoon Pharm. Co., LTD, a multi-million pharmaceutical company in South Korea.

Description

Generic Name:

KETOROLAC

Brand Name:

Ketorolex

Sizes:

30 mg/mL in ampoule

Preparation:

30 mg/mL in ampoule; Solution for Injection (IM/IV)

Name of Manufacturer

Myungmoon Pharmaceutical Co. Ltd.

Place of Manufacturer:

South Korea

Shelf Life

36 months

Storage Condition:

Store at temperature not exceeding 30 ͦC Protect from light

Packaging:

Amber glass ampoule (Box of 10’s)

FDA Registration:

DRP-2382-06

TRAMADOL

TRAMADEX

DISCLAIMER: The following contents are intended for healthcare professionals only. If you are a patient or general mass viewing this site, we advise you to clarify with your doctor any information you read herein.

Overview

TRAMADEX is produced by Ahngook Pharmaceutical Co., Ltd, a reputable company in South Korea with a Certificate of Current Good Manufacturing Practice (cGMP). It has developed and supplied outstanding medicines for the last forty (45) years in the pharmaceutical industry.

According to a study, the medication is used to help relieve moderate to moderately severe pain and works in the brain to change how your body feels and responds to pain.

Description

Generic Name:

TRAMADOL

Brand Name:

TRAMADEX

Sizes:

50 mg/mL (100 mg/2 mL) in ampoule

Preparation:

50 mg/mL (100 mg/2 mL) in ampoule; Solution for Injection (IM\IV)

Name of Manufacturer

Ahngook Pharmaceutical Co. Ltd.

Place of Manufacturer:

South Korea

Shelf Life

36 months

Storage Condition:

Store at temperature not exceeding 25 ͦC

Packaging:

Type I Amber glass ampoule (Box of 10’s)

FDA Registration:

DR-XY27009

  • 800 Third Avenue Suite A #1359, New York, NY 10022, USA
  • Lot 4, Blk 4, Carnation cor. Magnolia St., Brgy. Sauyo, Quezon City, 1116, Philippines.

COMPANY

INVEST

TERMS

Copyrights

COPYRIGHTS

Copyrights © DELEX 2023. All rights reserved.

This website and its content are copyright of Delex Healthcare Group Inc. (D
Any redistribution or reproduction of any contents or images in any form is prohibited other than the following:

You may print or download to local hard disk extracts for your personal and non-commercial use only. You may not, except with our express written permission, distribute or commercially exploit any contents or images. You may not copy or transmit it or store it in any other website, blogs or social media pages, or other forms of the electronic retrieval system.

 

Copyrights © DELEX 2023. All rights reserved.
Disclaimers

DISCLAIMERS

DISCLAIMERS

 

Investing in any business involves risks, illiquidity, lack of dividends, loss of investment, dilution of shares, and should be done only as a part of a diversified portfolio. This presentation is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. This information has not been approved as a financial promotion, and you must carry out your own due diligence.

 

This presentation file is for informational purposes only and does not constitute an offer or solicitation to sell shares or securities in the Company or any related or associated company. Any such offer or solicitation will be made only by means of the Company’s confidential Offering Memorandum and in accordance with the terms of all applicable securities and other laws. None of the information or analyses presented are intended to form the basis for any investment decision, and no specific recommendations are intended.

 

Accordingly, this presentation file does not constitute investment advice or counsel or solicitation for investment in any security. This presentation file does not constitute or form part of, and should not be construed as, any offer for sale or subscription of, or any invitation to offer to buy or subscribe for, any securities, nor should it or any part of it form the basis of, or be relied on in any connection with, any contract or commitment whatsoever. Delex Healthcare Group Inc. (Delex), Delex Pharma International Inc. (Delex Pharma) and or DLX Holdings (DLX) expressly disclaims any and all responsibility for any direct or consequential loss or damage of any kind whatsoever arising directly or indirectly from: (i) reliance on any information contained on the website, (ii) any error, omission or inaccuracy in any such information or (iii) any action resulting therefrom.

 

RISK FACTORS

An investment in our Common Stock involves a high degree of risk. You should carefully consider the following risk factors, together with the other information contained in this Offering Circular, before purchasing our Common Stock. Any of the following factors could harm our business, financial condition, results of operations or prospects, and could result in a partial or complete loss of your investment. Some statements in this Offering Circular, including statements in the following risk factors, constitute forward-looking statements. Please refer to the section entitled “Cautionary Statement Regarding Forward-Looking Statements”.

 

Risks Relating to Our Financial Condition

We may require additional capital to support business growth, and this capital might not be available on acceptable terms, if at all.

 

We intend to continue to make investments to support our business growth and may require additional funds to respond to business challenges, including the need to develop new features and products or enhance our existing products, improve our operating infrastructure or acquire complementary businesses and technologies. Accordingly, we may need to engage in continued equity or debt financings to secure additional funds. If we raise additional funds through future issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of our common stock. Any debt financing, we secure in the future, could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to support our business growth and to respond to business challenges could be impaired, and our business may be harmed.

 

Risks Relating to Our Business and Industry

We may fail to obtain sufficient capital resources for future growth and other operational needs.

 

We require additional capital resources to pursue our growth strategy through organic expansion as well as strategic investments and acquisitions and to remain competitive by responding in a timely manner to technological changes or market demand. We require significant capital to build, maintain, operate and expand our research and development activities, develop more product range, secure more distribution rights, expand its global distribution channels, invest in manufacturer of healthcare products and provider of healthcare services.

 

We expect to meet our funding needs through cash flows from operations, securities offerings, bank borrowings and other external financing sources. Our ability to obtain additional financing will depend on several factors, including our financial condition, results of operations and cash flows. The increase in the interest rates and statutory deposit reserve ratios tightened credit and negatively affected the abilities of many companies to borrow from financial institutions. If we cannot obtain sufficient funding on acceptable terms or, to the extent required, receive necessary approvals for our financing plans from the regulatory authorities, we may not be able to successfully implement our business strategy, and our prospects could be materially and adversely affected.

 

We may experience significant losses from operations.

 

Even if we do generate operating income in one or more quarters in the future, subsequent developments in our industry, customer base, business or cost structure or an event such as significant litigation or a significant transaction may cause us to again experience operating losses. We may not become profitable for the long-term, or even for any

We may not be able to successfully identify acquisition targets or complete acquisitions or integrate the acquired businesses.

 

We may not be able to successfully identify acquisition targets or complete acquisitions or integrate the acquired businesses. One of our business strategies is to take advantage of the trend of consolidation in the highly fragmented healthcare industry by undertaking acquisition activities. Further, we intend to use part of the net proceeds that we receive from the listing to acquire domestic and overseas healthcare businesses. Through acquisitions, we aim to obtain advanced technologies, new products and other resources for our pharmaceutical manufacturing business, diagnostic products, and medical devices businesses, enter and expand our operations in the premium, specialty, and general healthcare service markets in the Philippines, and expand the coverage and network of our retail pharmacies in our existing and future target markets in the whole of Asia. Internationally, we plan to primarily acquire overseas generic drug manufacturing companies or specialty pharmaceutical companies with strong product portfolios, research, and development. These overseas pharmaceutical companies are expected to help us further expand our product lines and increase the sales of our products in the international markets. In addition, we may continue to identify, pursue, and consummate joint venture projects in the future.

 

Risks Relating To The Company’s Securities

 

We may never have a public market for our common stock or may never trade on a recognized exchange. Therefore, you may be unable to liquidate your investment in our stock.

 

There is no established public trading market for our securities. Our shares are not and have not been listed or quoted on any exchange or quotation system.

 

For our shares to be quoted, a market maker must agree to file the necessary documents with the National Association of Securities Dealers, which operates the OTCQB. In addition, it is possible that such application for quotation may not be approved and even if approved it is possible that a regular trading market will not develop or that if it did develop, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.

We do not expect to declare or pay dividends in the foreseeable future.

We do not expect to declare or pay dividends in the foreseeable future, as we anticipate that we will invest future earnings in the development and growth of our business. Therefore, holders of our Common Stock will not receive any return on their investment unless they sell their securities, and holders may be unable to sell their securities on favorable terms or at all.

 

 Our shares are subject to the penny stock rules, making it more difficult to trade our shares.

 

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If the price of our Common Stock is less than $5.00, our Common Stock will be deemed a penny stock. The penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i) the purchaser’s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our Common Stock, and therefore stockholders may have difficulty selling their shares. 

 

Cautionary Statement Regarding Forward-Looking Statements

 

This Offering Circular contains various “forward-looking statements.” You can identify forward-looking statements by the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “would,” “could,” “should,” “seeks,” “approximately,” “intends,” “plans,” “projects,” “estimates” or “anticipates” or the negative of these words and phrases or similar words or phrases. You can also identify forward-looking statements by discussions of strategy, plans or intentions. These statements may be impacted by several risks and uncertainties. The forward-looking statements are based on our beliefs, assumptions and expectations of our future performance considering all information currently available to us. These beliefs, assumptions and expectations are subject to risks and uncertainties and can change as a result of many possible events or factors, not all of which are known to us. If a change occurs, our business, financial condition, liquidity, and results of operations may vary materially from those expressed in our forward-looking statements. You should carefully consider these risks before you make an investment decision with respect to our Securities. For a further discussion of these and other factors that could impact our future results, performance, or transactions, see the section entitled “Risk Factors.”

 

We are selling the shares of this offering without an underwriter and may be unable to sell any shares.

 

This offering is self-underwritten, that is, we are not going to engage the services of an underwriter to sell the shares; we intend to sell our shares through our Chairman of our Board of Directors and CEO, Mr. Oroceo and Servebank Financial Inc., (Servebank), both of whom will receive no commissions. There is no guarantee that Mr. Oroceo or Servebank will be able to sell any of the shares. Unless they are successful in selling all of the shares of our Company’s offering, we may have to seek alternative financing to implement our business plan.

 

FORWARD LOOKING STATEMENTS

The statements contained herein may contain certain forward-looking statements relating to Delex Healthcare Group, Inc. or “Delex” that are based on the beliefs of Delex as well as assumptions made by and information currently available to Delex’s management. These forward-looking statements are, by their nature, subject to significant risks and uncertainties. These forward-looking statements include, without limitation, statements relating to Delex’s business prospects, future developments, trends and conditions in the industry and geographical markets in which Delex operates, its strategies, plans, objectives and goals, its ability to control costs, statements relating to prices, volumes, operations, margins, capital expenditures, overall market trends, risk management and exchange rates. When used herein, the words “anticipate”, “believe”, “could”, “estimate”, “expect”, “going forward”, “intend”, “may”, “ought to”, “plan”, “project”, “seek”, “should”, “will”, “would” and similar expressions, as they relate to Delex or Delex’s management, are intended to identify forward-looking statements. These forward-looking statements reflect Delex’s views at the time such statements were made with respect to future events and are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including any changes in the laws, rules and regulations relating to any aspects of Delex’s business operations, general economic, market and business conditions, including capital market developments, changes or volatility in interest rates, foreign exchange rates, equity prices or other rates or prices, the actions and developments of the Delex’s competitors and the effects of competition in the healthcare or related sectors, demand for, and price of, Delex’s products and services, various business opportunities that Delex may or may not pursue, changes in population growth and other demographic trends, including mortality, pandemics, morbidity and longevity rates, persistency levels, Delex’s ability to identify, measure, monitor and control risks in Delex’s business, including its ability to manage and adapt its overall risk profile and risk management practices, its ability to properly price its products and services, including capital expenditures and establish reserves for future policy benefits and claims, seasonal fluctuations and factors beyond Delex’s control. Subject to the requirements of the Listing Rules, Delex does not intend to update or otherwise revise such forward-looking statements, whether as a result of new information, future events or otherwise. As a result of these and other risks, uncertainties and assumptions, forward-looking events and circumstances discussed herein might not occur in the way Delex expects, or at all. Accordingly, you should not place reliance on any forward-looking information or statements. All forward-looking statements herein are qualified by reference to the cautionary statements set forth in this section.

 

Copyrights © DELEX 2023. All rights reserved.
Privacy Policy

PRIVACY POLICY

Your privacy is important to DELEX

This privacy statement provides information about the personal information that DELEX collects and how DELEX uses that personal information.

Personal Information Collection

DELEX may collect and use the following kinds of personal information:

Information about your use of this website Information about transactions carried out over this website.
Information that you provide to secure our services.

 

Using Personal Information

DELEX may use your personal information to:
Administer this website
Communicate with you.

Collect payments from you
Send account statements to you.

Publish information about you on the website.

Send invoices and demand payments from you.
Send information of products and or services to you.

Where DELEX discloses your personal information to its associates, partners, agents or sub-contractors for these purposes, the associates, partners, agent or sub-contractor in question will be obligated to use that personal information in accordance with the terms of this privacy statement.


In addition to the disclosures reasonably necessary for the purposes identified elsewhere above, DELEX may disclose your personal information to the extent that it is required to do so by law, in connection with any legal proceedings or prospective legal proceedings, and to establish, exercise or defend its legal rights.

Securing Your Data

DELEX will take reasonable technical and organizational precautions to prevent the loss, misuse, or alteration of your personal information.
DELEX will store all the personal information you provide on its secure servers. Information relating to electronic transactions entered via this website will be protected by encryption technology.

Cross-Border Data Transfers

Information which DELEX collects may be stored and processed in and transferred between any of the countries in which DELEX operates to enable the use of the information in accordance with this privacy policy.

In addition, personal information that you submit for publication on the website will be published on the internet and may be available around the world. You agree to such cross-border transfers of personal information.

Updating This Statement

DELEX may update this privacy policy by posting a new version on this website.
You should check this page occasionally to ensure you are familiar with any changes.

Other Websites

This website contains links to other websites
DELEX is not responsible for the privacy policies or practices of any third party.

 

Copyrights © DELEX 2023. All rights reserved.
Terms of Use

TERMS OF USE

Terms of Use

Welcome to our website. If you continue to browse and use this website, you are agreeing to comply with and be bound by the following terms and conditions of use, which together with our privacy policy govern DELEX’s relationship with you in relation to this website. If you disagree with any part of these terms and conditions, please do not use our website.


The terms, ‘DELEX or ‘us’ or ‘we’ or ‘Company’, refer to the owner of the website.

The term ‘you’ refers to the user or viewer of our website.


The use of this website is subject to the following terms of use:

The content of the pages of this website is for your general information and use only. It is subject to change without notice This website uses cookies to monitor browsing preferences.


Neither we nor any third parties provide any warranty or guarantee as to the accuracy, timeliness, performance, completeness or suitability of the information and materials found or offered on this website for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law

Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.

 
This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the logo, design, layout, look, appearance, and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions. All trademarks reproduced in this website, which is not the property of, or licensed to, the operator are acknowledged on the website Unauthorized use of this website may give rise to a claim for damages and/or be a criminal offense.


From time to time this website may also include links to other websites. These links are provided for your convenience to provide further information. Links to other websites do not signify that we endorse the website(s). We have no responsibility for the content of the linked website(s). Your use of this website and any dispute arising out of such use of the website is subject to the laws of the Philippines and the United States of America (USA).

Copyrights © DELEX 2023. All rights reserved.

Email us

info@delexhealth.com

Call us

+639985885514

© 2024 DELEX Healthcare Group. All Rights Reserved.

INVEST NOW